Between a Rock and a Hard Plaque: The Relationship Between LDL-C and ASCVD Risk and Improving Patient Outcomes with PCSK9 Inhibitors

In this program, experts will review updated guideline recommendations for ASCVD risk assessment and treatment; explore optimizing treatment with statin and nonstatin medications; and describe strategies for overcoming barriers to achieving LDL-C thresholds. 

Location
Rio Verde
Double Tree by Hilton Scottsdale Resort
Scottsdale, AZ

Date
Friday, June 5
10:30 - 11:30 a.m. PT

Map

Featuring

Bruce A. Warden

PharmD, PharmD, CLS, FNLA, FASPC, FAHA

Clinical Pharmacist, General Cardiology
Knight Cardiovascular Institute, Oregon Health & Science University
Portland, Oregon

Target Audience

• Identify patients at high risk for ASCVD and with clinical ASCVD requiring lipid screening and ASCVD risk stratification. 
• Summarize the impact of LDL-C on ASCVD and the importance of achieving LDL-C thresholds to reduce the risk of ASCVD events. 
• Apply current guideline-based treatment recommendations for patients at high risk for ASCVD and with clinical ASCVD. 

Agenda

• 10:45 a.m. – Welcome and Introduction
• 10:50 a.m. – Overview of Atherosclerosis
• 11:00 a.m. – Evidence-Based Management of Hypercholeserolemia
• 11:10 a.m. – Statin and Nonstatin Medications
• 11:25 a.m. – Achieving Recommended LDL-C Thresholds to Reduce ASCVD Event Risk
• 11:35 a.m. – Faculty Discussion, Questions and Answers

Accredited for CPE

ACPE #: 0204-0000-26-407-L01-P
CE Credit: 1.0 contact hour (0.10 CEUs)
Activity Type: Application-based
Activity Fee: No charge 

To Claim CE for the presentation, enter the CE code announced during the activity and complete the evaluation.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Provided by ASHP.
Supported by an educational grant from Merck.

For questions and assistance to participate, contact us.